Paracetamol Study in Patients With Low Muscle Mass

Inclusion Criteria: * \- Patients: Men, women and children diagnosed with/biochemically verified SMA and CP * Patients admitted to the ICU: Men, women, children diagnosed with/biochemically verified SMA and CP * Healthy controls: Need to be healthy, evaluated by the investigator. * Age: * Children: 6-18 years * Adult patients: 18-45 years * Healthy controls: 18-45 years * ICU-admitted patients: 6-45 years * Signed informed consent to participation in the trial Exclusion Criteria: * \- Inability to understand the purpose of the trial or cooperate in the conduction of the experiments. o For the children this will concern of course the parents or the guardians of the child. * Competing conditions at risk for compromising the results of the study. * Participation in other trials that may interfere with the results. * Intake of medications that may interfere with the results, evaluated by investigator. * Pregnancy and breastfeeding. * BMI \>30\* * In morbidly obese patients, the median area under the plasma concentration-time curve from 0 to 8 h. (AUC0-8h) of paracetamol is significantly smaller (p = 0.009), while the AUC0-8h ratios of the glucuronide, sulphate and cysteine metabolites to paracetamol are significantly higher (p = 0.043, 0.004 and 0.010, respectively). In this model, paracetamol CYP2E1-mediated clearance (cysteine and mercapturate) increased with lean body weight.